The activity of isoxazolyl penicillins in experimental staphylococcal infection.
Renneberg
J
J
Department of Medical Microbiology, University of Lund, Malmö, Sweden.
Forsgren
A
A
D000818:Animals; D019818:Clavulanic Acid; D002969:Clavulanic Acids / Q000627:therapeutic use; D003023:Cloxacillin / Q000493:pharmacokinetics / Q000627:therapeutic use; D004009:Dicloxacillin / Q000493:pharmacokinetics / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005436:Floxacillin / Q000493:pharmacokinetics / Q000627:therapeutic use; D006207:Half-Life; D006863:Hydrogen-Ion Concentration; D008712:Methicillin / Q000493:pharmacokinetics / Q000627:therapeutic use*; D051379:Mice; D008807:Mice, Inbred BALB C; D010068:Oxacillin / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011485:Protein Binding; D013203:Staphylococcal Infections / Q000188:drug therapy*; D013211:Staphylococcus aureus / Q000187:drug effects
D002969:Clavulanic Acids; D019818:Clavulanic Acid; D005436:Floxacillin; D004009:Dicloxacillin; D003023:Cloxacillin; D008712:Methicillin; D010068:Oxacillin